Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993).
Forty-eight dogs with histologically confirmed appendicular osteosarcoma (OSA) entered a prospective clinical trial evaluating treatment with amputation and up to 4 doses of carboplatin given every 21 days. The median disease-free interval (DFI) was 257 days, with 31.2% of the dogs disease-free at 1 year. The median survival time was 321 days, with 35.4% of the dogs alive at 1 year. Dogs with proximal humeral OSA had shorter DFI (P = .016) and survival (P = .037) times than dogs with OSA at other locations. Dogs with lower body weights ( < 40 kg) had longer DFI (P = .0056) and survival (P = .007) times than larger dogs. Survival times for dogs that received carboplatin were statistically longer than those previously reported for amputation alone (P < .001). DFI and survival times are similar to those previously reported for 2 to 4 doses of cisplatin. Carboplatin appears to be a well-tolerated chemotherapeutic drug that can be given safely every 21 days at a dose of 300 mg/m2. Neutropenia was the dose-limiting toxicity in this study.
Bergman
P J
PJ
Colorado State University, Fort Collins.
MacEwen
E G
EG
Kurzman
I D
ID
Henry
C J
CJ
Hammer
A S
AS
Knapp
D W
DW
Hale
A
A
Kruth
S A
SA
Klein
M K
MK
Klausner
J
J
Norris
A M
AM
McCaw
D
D
Straw
R C
RC
Withrow
S J
SJ
D000671:Amputation, Surgical; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000628:therapy / Q000662:veterinary*; D016190:Carboplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004283:Dog Diseases / Q000628:therapy*; D004285:Dogs; D005260:Female; D008297:Male; D012516:Osteosarcoma / Q000628:therapy / Q000662:veterinary*; D011379:Prognosis; D011446:Prospective Studies; D016019:Survival Analysis
D000970:Antineoplastic Agents; D016190:Carboplatin